Trial Profile
To evaluate safety and efficacy of Cetuximab + cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2015
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Oct 2015 New trial record